February 8, 2008 |
In one of the biggest U.S. healthcare fraud settlements ever, Merck & Co. will pay $671 million to settle claims it overcharged the government for four popular drugs and bribed doctors to prescribe its drugs, federal prosecutors said Thursday.
January 26, 2008 |
U.S. regulators said Friday that they would review whether to take action over Merck & Co. and Schering-Plough Corp.'s popular cholesterol drug Vytorin after a study showed it was no better than a generic in preventing the buildup of fatty plaque in blood vessels. The Food and Drug Administration said it had not received a final report on the study, called Enhance. The agency's review of Vytorin will take about six months after final results are received, the FDA said.
January 23, 2008 |
Merck & Co. and Schering-Plough Corp. suspended television ads Tuesday for the cholesterol pills Vytorin and Zetia after a study questioned the benefit of the medicines. The Vytorin commercials were among the most widely aired drug ads, featuring people dressed as food items to show the pill lowers cholesterol from food as well as from genetics. The ads were voluntarily and temporarily halted, Schering-Plough spokesman Lee Davies said.
January 19, 2008 |
More than 3,000 former users of Merck & Co.'s withdrawn Vioxx pain drug have signed up to take part in a $4.85-billion settlement deal that a federal judge said Friday was in the best interests of both sides. Lawyers for Merck and plaintiffs who claim to have been harmed by Vioxx were in U.S. District Court to give a status report on the settlement to Judge Eldon Fallon, who had presided over all federal Vioxx trials and is overseeing the settlement process.
December 14, 2007 |
The government should reject Merck & Co. Inc.'s third bid to sell a cholesterol-lowering pill without a doctor's prescription, an advisory panel ruled. Advisors to the Food and Drug Administration voted 10 to 2 with one abstention against Merck's proposal for a low-dose, over-the-counter version of its cholesterol fighter Mevacor. FDA officials usually follow the panel's recommendations.
November 10, 2007 |
Merck & Co.'s decision to pay $4.85 billion to settle tens of thousands of claims from patients who took the popular painkiller Vioxx may stiffen the resolve of other companies facing litigation over pharmaceutical products or other consumer goods. The settlement, announced Friday, may also vindicate the drug maker's initial strategy of aggressively fighting virtually every injury claim, legal experts said.